Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease

Hepatology

Volumn 47, Issue 2, 2008, Pages 484-492

  Charlton, Michael ^a   Angulo, Paul ^a   Chalasani, Naga ^b   Merriman, Ralph ^c   Viker, Kimberly ^a   Charatcharoenwitthaya, Phunchai ^a   Sanderson, Schuyler ^a   Gawrieh, Samer ^d   Krishnan, Anuradha ^a   Lindor, Keith ^a  

^a MAYO CLINIC   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRASTERONE SULFATE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; VALIDATION PROCESS;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; BIOPSY; BLOOD GLUCOSE; C-REACTIVE PROTEIN; COHORT STUDIES; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FATTY LIVER; FEMALE; HUMANS; LEPTIN; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; REFERENCE VALUES; RESISTIN;

EID: 39549088317     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22063     Document Type: Article

References (47)

1. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. HEPATOLOGY 1990;12:1106-1110.
2. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-1058.
3. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802-1805.
4. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614.
5. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003;37:917-923. Erratum in: HEPATOLOGY 2003;38:536.
6. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
7. Oliveira CP, Costa Gayotto LC, Tatai C, Della Bina BI, Janiszewski M, Lima ES, et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J Cell Mol Med 2002;6:399-406.
8. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1999;30:1356-1362.
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
10. Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. HEPATOLOGY 2003;38:244-251.
11. Bednarek-Tupikowska G, Gosk I, Szuba A, Bohdanowicz-Pawlak A, Kosowska B, Bidzinska B, et al. Influence of dehydroepiandrosterone on platelet aggregation, superoxide dismutase activity and serum lipid peroxide concentrations in rabbits with induced hypercholesterolemia. Med Sci Monit 2000;6:40-45.
12. Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, Trifiletti A, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001;145:457-461.
13. Jakubowicz D, Beer N, Rengifo R. Effect of dehydroepiandrosterone on cyclic-guanosine monophosphate in men of advancing age. Ann N Y Acad Sci 1995;774:312-315.
14. Kawano M. Complement regulatory proteins and autoimmunity. Arch Immunol Ther Exp (Warsz) 2000;48:367-372.
15. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 2005;54:765-769.
16. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833-32841.
17. Peters JM, Zhou YC, Ram PA, Lee SS, Gonzalez FJ, Waxman DJ. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol Pharmacol 1996;50:67-74.
18. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. HEPATOLOGY 2004;39:909-914.
19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
20. Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992;75:1002-1004.
21. Labrie F, Belanger A, Simard J, Van LT, Labrie C. DHEA and peripheral androgen and estrogen formation: intracinology. Ann N Y Acad Sci 1995;774:16-28.
22. Rainey WE, Carr BR, Sasano H, Suzuki T, Mason JI. Dissecting human adrenal androgen production. Trends Endocrinol Metab 2002;13:234-239.
23. Osathanondh R, Fencl MD, Schiff I, Himmel M, Tulchinsky D. Reduced urinary and serum total estriol levels in pregnancies after colectomy. Obstet Gynecol 1979;53:664-667.
24. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 1998;49:421-432.
25. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-1367. Erratum in: J Clin Endocrinol Metab 1995;80:2799.
26. Vogiatzi MG, Boeck MA, Vlachopapadopoulou E, el Rashid R, New MI. Dehydroepiandrosterone in morbidly obese adolescents: effects on weight, body composition, lipids, and insulin resistance. Metabolism 1996;45:1011-1015.
27. Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990;71:696-704.
28. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004;292:2243-2248.
29. Gu S, Ripp SL, Prough RA, Geoghegan TE. Dehydroepiandrosterone affects the expression of multiple genes in rat liver including 11 beta-hydroxysteroid dehydrogenase type 1: a cDNA array analysis. Mol Pharmacol 2003;63:722-731.
30. Vermeulen A. The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab 1976;42:247-253.
31. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988;66:57-61.
32. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992;117:807-811.
33. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002;37:56-62.
34. Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. HEPATOLOGY 1999;29:1131-1138.
35. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-1664.
36. Celebi F, Yilmaz I, Aksoy H, Gumus M, Taysi S, Oren D. Dehydroepiandrosterone prevents oxidative injury in obstructive jaundice in rats. J Int Med Res 2004;32:400-405.
37. Goto H, Yamashita S, Makita T. Preventive effects of dehydroepiandrosterone acetate on the fatty liver induced by orotic acid in male rats. Exp Anim 1998;47:257-260.
38. Mastrocola R, Aragno M, Betteto S, Brignardello E, Catalano MG, Danni O, et al. Pro-oxidant effect of dehydroepiandrosterone in rats is mediated by PPAR activation. Life Sci 2003;73:289-299.
39. Iwasaki T, Mukasa K, Yoneda M, Ito S, Yamada Y, Mori Y, et al. Marked attenuation of production of collagen type I from cardiac fibroblasts by dehydroepiandrosterone. Am J Physiol Endocrinol Metab 2005;288:E1222-E1228.
40. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. HEPATOLOGY 2001;34:1158-1163.
41. Tafani M, Schneider TG, Pastorino JG, Farber JL. Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition. Am J Pathol 2000;156:2111-2121.
42. Pastorino JG, Simbula G, Yamamoto K, Glascott PA Jr, Rothman RJ, Farber JL. The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition. J Biol Chem 1996;271:29792-29798.
43. Hildebrand F, Pape HC, Hoevel P, Krettek C, van Griensven M. The importance of systemic cytokines in the pathogenesis of polymicrobial sepsis and dehydroepiandrosterone treatment in a rodent model. Shock 2003;20:338-346.
44. Chang DM, Chu SJ, Chen HC, Kuo SY, Lai JH. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Ann Rheum Dis 2004;63:1623-1626.
45. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
46. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003;38:434-440.
47. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. 2004;39:188-196.